Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Agnarsson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|August 1, 1996
TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival materialS Gretarsdottir, L Tryggvadottir, J G Jonasson, et al.
Laeknabladid|January 13, 2010
[DNA flow cytometry is a useful prognostic guide in the treatment of breast cancer.]S Gudlaugsdottir, H Sigurdsson, B A Agnarsson, et al.
Scandinavian Journal of Immunology|October 12, 2013
The role of Th17/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic responseJ H Eysteinsdóttir, B Sigurgeirsson, J H Ólafsson, et al.
International Journal of Cancer|December 20, 1995
Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regionsG Eiriksdottir, A Sigurdsson, J G Jonasson, et al.
Cancer Research|April 1, 1997
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutationsM Tirkkonen, O Johannsson, B A Agnarsson, et al.
Human Genetics|December 29, 2000
Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancerJ T Bergthorsson, G Johannesdottir, A Arason, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosisG Eiriksdottir, G Johannesdottir, S Ingvarsson, et al.
Cancer Research|June 11, 1999
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomasS Ingvarsson, B A Agnarsson, B I Sigbjornsdottir, et al.
Cancer Research|August 15, 1996
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patientsG Johannesdottir, J Gudmundsson, J T Bergthorsson, et al.
Cancer Research|October 10, 1998
High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutationS Ingvarsson, E K Geirsdottir, G Johannesdottir, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|August 1, 1996
TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival materialS Gretarsdottir, L Tryggvadottir, J G Jonasson, et al.
Laeknabladid|January 13, 2010
[DNA flow cytometry is a useful prognostic guide in the treatment of breast cancer.]S Gudlaugsdottir, H Sigurdsson, B A Agnarsson, et al.
Scandinavian Journal of Immunology|October 12, 2013
The role of Th17/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic responseJ H Eysteinsdóttir, B Sigurgeirsson, J H Ólafsson, et al.
International Journal of Cancer|December 20, 1995
Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regionsG Eiriksdottir, A Sigurdsson, J G Jonasson, et al.
Cancer Research|April 1, 1997
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutationsM Tirkkonen, O Johannsson, B A Agnarsson, et al.
Human Genetics|December 29, 2000
Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancerJ T Bergthorsson, G Johannesdottir, A Arason, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosisG Eiriksdottir, G Johannesdottir, S Ingvarsson, et al.
Cancer Research|June 11, 1999
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomasS Ingvarsson, B A Agnarsson, B I Sigbjornsdottir, et al.
Cancer Research|August 15, 1996
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patientsG Johannesdottir, J Gudmundsson, J T Bergthorsson, et al.
Cancer Research|October 10, 1998
High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutationS Ingvarsson, E K Geirsdottir, G Johannesdottir, et al.
Pageof 5